The Truth About the New Oral GLP-1 Medications (Ozempic Pill Update)
Spencer Nadolsky, DOPublished on October 23, 2025
Summary authored by editor@wellifi.com
TLDR Summary
The podcast discusses the Oasis 4 trial results for oral semaglutide, showing significant weight loss and the introduction of orforg, a new small molecule GLP-1 receptor agonist. Both therapies promise to enhance obesity treatment options and improve patient adherence.
Key Points
- Oasis 4 trial demonstrated a 13.6% weight loss over 64 weeks with oral semaglutide.
- Participants experienced a 16.6% weight loss with consistent treatment.
- Oral semaglutide requires precise intake guidelines for maximum efficacy.
- Orforg, a new small molecule GLP-1 receptor agonist, offers higher bioavailability and greater convenience.
Understanding the Latest in Oral GLP-1 Therapies for Weight Management
Welcome back to the Docs Who Lift podcast! In this episode, host Dr. Spencer Nadolsky and co-host Dr. Carl are joined by the esteemed Dr. Sean Warren to discuss groundbreaking developments in the field of obesity medicine, specifically focusing on the recent publication of the Oasis 4 trial and the introduction of new oral GLP-1 receptor agonists.
The Oasis 4 Trial: Oral Semaglutide's Journey
The Oasis 4 trial has brought to light the efficacy of oral semaglutide, a medication that has been previously approved for type 2 diabetes. This trial specifically examined a 25 mg dose, and the results have shown promising outcomes for weight management.
Key Findings from Oasis 4
- Participants in the trial experienced a weight loss of approximately 13.6% after 64 weeks.
- For those who adhered to the treatment protocol, the weight loss increased to 16.6%.
- Oral semaglutide demonstrated similar efficacy to its injectable counterpart.
- The medication must be taken in the morning with exactly 4 ounces of water, separate from food and other medications.
The Mechanism Behind Oral Semaglutide
Oral semaglutide is designed to overcome the challenges of delivering large protein molecules through the gastrointestinal tract. While only about 1-4% of the active pharmaceutical ingredient (API) enters the bloodstream, the design of the molecule allows it to be effective, offering a similar result to injections.
Comparing Oral Semaglutide to Other GLP-1 Therapies
Dr. Warren also introduced orforg, a small molecule GLP-1 receptor agonist, which promises to enhance the treatment landscape for obesity. Unlike larger peptide molecules, small molecules can be taken without stringent requirements regarding food intake, making them more convenient for patients.
Benefits of Orforg
- Higher bioavailability, potentially between 70-100%.
- No requirement to separate from food or medications.
- Lower cost potential due to efficient API usage.
Side Effects and Considerations
Both oral semaglutide and orforg have shown relatively low dropout rates due to adverse effects, with gastrointestinal issues being the most common. It’s important for practitioners to monitor patients' responses and adjust treatment accordingly.
Conclusion: A New Era for Weight Management
The discussions surrounding the Oasis 4 trial and the new GLP-1 receptor agonists signal a significant shift in obesity medicine. As more oral therapies become available, healthcare providers will have greater flexibility in treating patients with obesity and related conditions.
For those interested in these developments, sharing this information could provide valuable insights into managing weight effectively and understanding the evolving landscape of obesity treatments.